Unknown

Dataset Information

0

Preclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase.


ABSTRACT:

Purpose

Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that plays a major role in brain cholesterol homeostasis by converting cholesterol into 24S-hydroxycholesterol. The selective CH24H inhibitor soticlestat (TAK-935) is being pursued as a drug for treatment of seizures in developmental and epileptic encephalopathies. Herein, we describe the successful discovery and the preclinical validation of the novel radiolabeled CH24H ligand (3-[18F]fluoroazetidin-1-yl){1-[4-(4-fluorophenyl)pyrimidin-5-yl]piperidin-4-yl}methanone ([18F]T-008) and its tritiated analog, [3H]T-008.

Methods

In vitro autoradiography (ARG) studies in the CH24H wild-type (WT) and knockout (KO) mouse brain sections were conducted using [3H]T-008. PET imaging was conducted in two adult rhesus macaques using [18F]T-008. Each macaque received two test-retest baseline scans and a series of two blocking doses of soticlestat administered prior to [18F]T-008 to determine the CH24H enzyme occupancy. PET data were analyzed with Logan graphical analysis using plasma input. A Lassen plot was applied to estimate CH24H enzyme occupancy by soticlestat.

Results

In ARG studies, binding of [3H]T-008 was specific to CH24H in the mouse brain sections, which was not observed in CH24H KO or in wild-type mice after pretreatment with soticlestat. In rhesus PET studies, the rank order of [18F]T-008 uptake was striatum > cortical regions > cerebellum, which was consistent with CH24H distribution in the brain. Pre-blocking with soticlestat reduced the maximum uptake and increased the washout in all brain regions in a dose-dependent manner. Calculated global occupancy values for soticlestat at a dose of 0.89 mg/kg were 97-98%, indicating maximum occupancy.

Conclusion

The preclinical in vitro and in vivo evaluation of labeled T-008 demonstrates that [18F]T-008 is suitable for imaging CH24H in the brain and warrants further studies in humans.

SUBMITTER: Koike T 

PROVIDER: S-EPMC8921165 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preclinical characterization of [<sup>18</sup>F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase.

Koike Tatsuki T   Constantinescu Cristian C CC   Ikeda Shuhei S   Nishi Toshiya T   Sunahara Eiji E   Miyamoto Maki M   Cole Patricia P   Barret Olivier O   Alagille David D   Papin Caroline C   Morley Thomas T   Fowles Krista K   Seibyl John J   Tamagnan Gilles G   Kuroita Takanobu T  

European journal of nuclear medicine and molecular imaging 20211015 4


<h4>Purpose</h4>Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that plays a major role in brain cholesterol homeostasis by converting cholesterol into 24S-hydroxycholesterol. The selective CH24H inhibitor soticlestat (TAK-935) is being pursued as a drug for treatment of seizures in developmental and epileptic encephalopathies. Herein, we describe the successful discovery and the preclinical validation of the novel radiolabeled CH24H ligand (3-[<sup>18</sup>F]fluoroazetidin-1-yl){1  ...[more]

Similar Datasets

| S-EPMC6604685 | biostudies-literature
| S-EPMC7188736 | biostudies-literature